替西肽影响女性性功能:病例报告。

IF 0.8 Q3 MEDICINE, GENERAL & INTERNAL
Clinical Medicine Insights. Case Reports Pub Date : 2025-06-06 eCollection Date: 2025-01-01 DOI:10.1177/11795476251347753
Ghada Farouk Mohammed, Mohammed Saleh Al-Dhubaibi, Saleh Salem Bahaj, Rana Magdy Mohammed
{"title":"替西肽影响女性性功能:病例报告。","authors":"Ghada Farouk Mohammed, Mohammed Saleh Al-Dhubaibi, Saleh Salem Bahaj, Rana Magdy Mohammed","doi":"10.1177/11795476251347753","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Tirzepatide is a new molecule capable of controlling blood glucose levels by combining the dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucose-like peptide-1 (GLP-1) receptors. The Food and Drug Administration approved tirzepatide subcutaneous injections as monotherapy or combination therapy, with diet and physical exercise. Its influence on sexual behavior as an adverse effect is not well known.</p><p><strong>Aims: </strong>The purpose of this report was to present a case study of an obese female patient who received tirzepatide treatment for sexual dysfunction.</p><p><strong>Methods: </strong>We performed an extensive clinical evaluation, which included the Female Sexual Function Index (FSFI). Metabolic, hormonal, immunologic, and hematologic etiology of sexual dysfunction was ruled out by laboratory examination. The patient was managed by a multimodal approach, with lifestyle modification, pelvic floor strengthening exercises, pharmacologic management with bupropion sustained release 150 to 400 mg per day and topical lubricants, and psychosexual therapy as needed. FSFI scores were longitudinally followed to assess treatment response.</p><p><strong>Results: </strong>A 36-year-old woman with obesity class III developed sexual dysfunction after using tirzepatide, a healthy lifestyle with a carb cycle diet, greater physical activity, and exercise for losing weight. All physical, psychological, and hormonal parameters were normal. During treatment, the patient started to complain of decreasing sexual drive, genital dryness, and failure to catch orgasm; female sexual function index (FSFI) = 12.7. Symptoms decreased after stopping the tirzepetide (FSFI = 28.7) and reappeared after retaking the injection (FSFI = 14.7). After 1 month of sexual treatment and support, FSFI = 24.</p><p><strong>Conclusion: </strong>The drug's impact on hormones and neurological pathways may contribute to decreased sexual desire, through the specific process is unknown. Adjuvant sexual education and therapy support has an imperative role in the plan of management in cases on going in the journey of reducing their weight and complaining of sexual performance affection.</p>","PeriodicalId":10357,"journal":{"name":"Clinical Medicine Insights. Case Reports","volume":"18 ","pages":"11795476251347753"},"PeriodicalIF":0.8000,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144364/pdf/","citationCount":"0","resultStr":"{\"title\":\"Tirzepatide Affect Sexual Function in Women: Case Report.\",\"authors\":\"Ghada Farouk Mohammed, Mohammed Saleh Al-Dhubaibi, Saleh Salem Bahaj, Rana Magdy Mohammed\",\"doi\":\"10.1177/11795476251347753\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Tirzepatide is a new molecule capable of controlling blood glucose levels by combining the dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucose-like peptide-1 (GLP-1) receptors. The Food and Drug Administration approved tirzepatide subcutaneous injections as monotherapy or combination therapy, with diet and physical exercise. Its influence on sexual behavior as an adverse effect is not well known.</p><p><strong>Aims: </strong>The purpose of this report was to present a case study of an obese female patient who received tirzepatide treatment for sexual dysfunction.</p><p><strong>Methods: </strong>We performed an extensive clinical evaluation, which included the Female Sexual Function Index (FSFI). Metabolic, hormonal, immunologic, and hematologic etiology of sexual dysfunction was ruled out by laboratory examination. The patient was managed by a multimodal approach, with lifestyle modification, pelvic floor strengthening exercises, pharmacologic management with bupropion sustained release 150 to 400 mg per day and topical lubricants, and psychosexual therapy as needed. FSFI scores were longitudinally followed to assess treatment response.</p><p><strong>Results: </strong>A 36-year-old woman with obesity class III developed sexual dysfunction after using tirzepatide, a healthy lifestyle with a carb cycle diet, greater physical activity, and exercise for losing weight. All physical, psychological, and hormonal parameters were normal. During treatment, the patient started to complain of decreasing sexual drive, genital dryness, and failure to catch orgasm; female sexual function index (FSFI) = 12.7. Symptoms decreased after stopping the tirzepetide (FSFI = 28.7) and reappeared after retaking the injection (FSFI = 14.7). After 1 month of sexual treatment and support, FSFI = 24.</p><p><strong>Conclusion: </strong>The drug's impact on hormones and neurological pathways may contribute to decreased sexual desire, through the specific process is unknown. Adjuvant sexual education and therapy support has an imperative role in the plan of management in cases on going in the journey of reducing their weight and complaining of sexual performance affection.</p>\",\"PeriodicalId\":10357,\"journal\":{\"name\":\"Clinical Medicine Insights. Case Reports\",\"volume\":\"18 \",\"pages\":\"11795476251347753\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-06-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144364/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Medicine Insights. Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/11795476251347753\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights. Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795476251347753","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

tizepatide是一种结合了葡萄糖依赖性胰岛素性多肽(GIP)和葡萄糖样肽-1 (GLP-1)受体的双重激动作用而控制血糖水平的新分子。美国食品和药物管理局批准替西肽皮下注射作为单一疗法或联合疗法,并配合饮食和体育锻炼。它对性行为的负面影响尚不为人所知。目的:本报告的目的是介绍一例肥胖女性患者接受替西帕肽治疗性功能障碍的病例研究。方法:我们进行了广泛的临床评估,包括女性性功能指数(FSFI)。通过实验室检查,排除了代谢、激素、免疫和血液学的性功能障碍病因。患者采用多模式治疗,包括生活方式改变,骨盆底强化锻炼,安非他酮缓释150 - 400mg /天的药物治疗和局部润滑剂,以及必要的性心理治疗。纵向跟踪FSFI评分以评估治疗反应。结果:一名36岁肥胖III级女性在使用替西帕肽、碳水化合物循环饮食的健康生活方式、更多的体育活动和减肥运动后出现性功能障碍。所有生理、心理和激素参数均正常。在治疗期间,患者开始抱怨性欲下降,生殖器干燥,无法达到性高潮;女性性功能指数(FSFI) = 12.7。停用替西肽后症状减轻(FSFI = 28.7),重新注射后症状再次出现(FSFI = 14.7)。性治疗支持1个月后,FSFI = 24。结论:该药物对激素和神经通路的影响可能导致性欲下降,具体过程尚不清楚。辅助性教育和治疗支持在减肥和抱怨性行为影响的病例的管理计划中起着至关重要的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Tirzepatide Affect Sexual Function in Women: Case Report.

Introduction: Tirzepatide is a new molecule capable of controlling blood glucose levels by combining the dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucose-like peptide-1 (GLP-1) receptors. The Food and Drug Administration approved tirzepatide subcutaneous injections as monotherapy or combination therapy, with diet and physical exercise. Its influence on sexual behavior as an adverse effect is not well known.

Aims: The purpose of this report was to present a case study of an obese female patient who received tirzepatide treatment for sexual dysfunction.

Methods: We performed an extensive clinical evaluation, which included the Female Sexual Function Index (FSFI). Metabolic, hormonal, immunologic, and hematologic etiology of sexual dysfunction was ruled out by laboratory examination. The patient was managed by a multimodal approach, with lifestyle modification, pelvic floor strengthening exercises, pharmacologic management with bupropion sustained release 150 to 400 mg per day and topical lubricants, and psychosexual therapy as needed. FSFI scores were longitudinally followed to assess treatment response.

Results: A 36-year-old woman with obesity class III developed sexual dysfunction after using tirzepatide, a healthy lifestyle with a carb cycle diet, greater physical activity, and exercise for losing weight. All physical, psychological, and hormonal parameters were normal. During treatment, the patient started to complain of decreasing sexual drive, genital dryness, and failure to catch orgasm; female sexual function index (FSFI) = 12.7. Symptoms decreased after stopping the tirzepetide (FSFI = 28.7) and reappeared after retaking the injection (FSFI = 14.7). After 1 month of sexual treatment and support, FSFI = 24.

Conclusion: The drug's impact on hormones and neurological pathways may contribute to decreased sexual desire, through the specific process is unknown. Adjuvant sexual education and therapy support has an imperative role in the plan of management in cases on going in the journey of reducing their weight and complaining of sexual performance affection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Medicine Insights. Case Reports
Clinical Medicine Insights. Case Reports MEDICINE, GENERAL & INTERNAL-
CiteScore
1.10
自引率
0.00%
发文量
57
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信